Paclitaxel liposomal(Syncore Biotechnology)

N/A

Report date: 2025/01/22 16:05:29

Base Information

Drug NamePaclitaxel liposomal(Syncore Biotechnology)
Drug Alias Namelipid complexed paclitaxel(MediGene)Paclitaxel in cationic liposomes(Syncore Biotechnology)EndoTAG-1MBT-0206SB 05 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsNeoplasm MetastasisPancreatic NeoplasmsTriple Negative Breast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedigene Ag
China Registration ClassN/A

Develop Information

Active CompaniesSyncore Biotechnology Co Ltd
Inactive CompaniesJules Bordet InstituteMedigene Inc
Active IndicationsPancreatic Neoplasms
Inactive IndicationsNeoplasm MetastasisTriple Negative Breast NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A